The absence of routine testing for FLT3-ITD in APL, the lack of international standardized FLT3-ITD assays, and the rarity of the disease pose limitations for studies of FLT3-ITD APL [6,13]. This evidence concerns the gene FLT3 and acute promyelocytic leukemia.